welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.
expertly curated content related to this topic
-
@spoiled197071I fight cancer everyday! I hate you F.A....
-
Steven H. Itzkowitz, MDDr. Itzkowitz is past Chair of the Gastr...
-
Medizinische Universitätsklinik KnappschaftskrankenhausThe Knappschaftskrankenhaus is affiliate...
-
Thomas Garofalo, MDThomas Garofalo, MD, FACS, is a Staff Su...
-
Gatekeeper Role of Gastroenterologists and Surgeons in Recognising and Discussing Familial Colorectal CancerThis study aimed to gain insight into th...
-
Hidden Heartache: The Untold Story of Bowel CancerEvery 15 minutes someone is diagnosed wi...
-
Randall E. Brand, MDProfessor of Medicine Academic Director...